The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Masimo Corp.

  • MASI
  • NASDAQ
  • Consumer Products
  • Latest 26.34
  • Currency US$
  • Change -0.16
  • Percent Change -0.604 %
  • Volume 280,284
  • Wed Apr 16, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 26.69
  • Previous Close 26.50
  • High 26.69
  • Low 26.11
  • Bidx0 0.0000
  • Askx32 27.06
  • 52-week High01/24 32.20
  • 52-week Low04/17 19.08
  • Beta 1.006
  • Market Cap 1,489.00M
  • EPS 1.16
  • P/E 22.707
  • Forward P/E 19.95
  • PEG 1.50
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $547,240,000
  • Earnings $58,380,000
  • Return on Equity 18.24%

Cash Flow

  • Cash Flow --
  • Cash $95,460,000
  • Current Ratio 2.62

12 months ended Dec 31, 2013.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $438,660,000
  • Liabilities $112,260,000
  • Liabilities-to-Equity Ratio 0.34

Price Ratios

  • Price to Sales 2.72
  • Price to Book 4.56
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Feb 13 $0.31 May 1 $0.29
Surprises Oct 30 3.85% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Apr 16, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Masimo develops innovative monitoring technologies that significantly improve patient care -- helping solve unsolvable problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry's ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.

Related Securities
Symbol Type Latest % Chg

Officers

  • Joe Kiani Chairman of the Board & C.E.O.
  • Mark P. de Raad Exec. Vice President & C.F.O.
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

40 PARKER
IRVINE, CA
92618

Phone: (949)-297-7000
Fax: (949)-2977499


www.masimo.com

Ideas & Discussion

Live Discussion of MASI on StockTwits